

Brief Report

ARGONAUT-I: Activity of cefiderocol (S-649266), a siderophore cephalosporin, against Gram-negative bacteria including carbapenem resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum β -lactamases and carbapenemases

Michael R. Jacobs*, MD PhD¹, Ayman M. Abdelhamed, MD PhD², Caryn E. Good, MA/MPH³, Daniel D. Rhoads, MD², Kristine M. Hujer, BS^{4,5}, Andrea M. Hujer, BS^{4,5}, T. Nicholas Domitrovic, MS^{4,5}, Susan D. Rudin, BS^{4,5}, Sandra S. Richter, MD⁶, David van Duin, MD/PhD⁷, Barry N. Kreiswirth, PhD⁸, Chris Greco, PhD⁹, Derrick E. Fouts, PhD⁹, Robert A. Bonomo, MD*^{4,5,10} on behalf of the Antibacterial Resistance Leadership Group (ARLG)

Supplemental material

Figure S1. Structure of cefiderocol (S-649266).

Table S1. Interpretative breakpoints used.

Figure S1. Structure of cefiderocol (S-649266)




Table S1. Interpretative breakpoints used.

Agent	Range tested (mg/L)	Interpretative breakpoints (mg/L) ^{a,b}			
		Enterobacteriaceae	<i>Acinetobacter spp.</i>	<i>Pseudomonas aeruginosa</i>	<i>Stenotrophomonas maltophilia</i>
Cefiderocol	0.03-64	- ^c	-	-	-
Amikacin	4-64	≤16/32/>32	≤16/32/>32	≤16/32/>32	-
Ciprofloxacin	0.24-4	≤1/2/>2	≤1/2/>2	≤1/2/>2	-
Colistin	0.5-8	≤2/-/>2 ^d	≤2/-/>2	≤2/-/>2	≤2/-/>2 ^d
Tigecycline	0.25-4	≤2/4/>4 ^e	-	-	-
Aztreonam	0.5-32	≤4/8/>8	-	≤8/16/>16	-
Ceftolozane-tazobactam ^f	0.03-64	≤2/4/>4	-	≤4/8/>8	-
Cefepime	0.5-16	≤2/4-8 ^g />8	-	≤8/16/>16	-
Ceftazidime	0.03-64	≤4/8/>8	≤8/16/>16	≤8/16/>16	≤8/16/>16
Ceftazidime-avibactam ^f	0.03-64	≤8/-/>8	≤8/-/>8 ^d	≤8/-/>8	≤8/-/> 8 ^d
Meropenem	0.03-64	≤1/2/>2	≤2/4/>4	≤2/4/>4	-

^a Breakpoints shown as susceptible/intermediate/resistant values unless otherwise indicated

^b CLSI breakpoints (1) shown unless otherwise indicated

^c -, no interpretative breakpoints available; provisional susceptible breakpoint of ≤4 mg/L used for cefiderocol

^d Breakpoint for *P. aeruginosa* used

^e FDA breakpoint

^f Tazobactam and avibactam tested in fixed concentration of 4 mg/L with ceftolozane and ceftazidime, respectively

^g Susceptible, dose-dependent

References

1. Clinical and Laboratory Standards Institute. 2018. M100-S28. Performance Standards for Antimicrobial Susceptibility Testing, 28th Edition. Clinical and Laboratory Standards Institute, Wayne, PA.